Case study: becoming the first GMP-certified cell and gene therapy manufacturing facility in Thailand

Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.

Collaboration can help overcome process development and capacity expansion hurdles to enable the delivery of reproducible and scalable manufacturing processes for cell and gene therapies.

Genepeutic Bio is a CDMO founded in 2020 to deliver the next wave of personalized cell and gene therapy for patients in Asia, initiating with chimeric antigen receptor (CAR) T cells. This GMP facility complies with international standards utilizing the latest technology of CAR T to fight cancer and bolster patient safety through extensive quality control.

In this webinar, we’ll discuss our journey in becoming the first GMP-certified cell and gene therapy manufacturing facility in Thailand. You’ll also discover more about the importance of PD optimization, closing and automating workflows, training, project management, tech transfer, and the key lessons learned along the way.

• Understand how to overcome some of the hurdles to achieving GMP manufacturing
• Learn more about process development capabilities required to better support cGMP manufacturing
• Gain industry-relevant insight from a case study for developing GMP-compliant facilities in Asia
• Discover how to apply lessons learned to help streamline your capacity expansion project to support patients in need

Kitipong Uaesoontrachoon

Chief Scientific Officer at Genepeutic Bio Co.,Ltd

Dr Uaesoontrachoon has been involved in the gene therapy field for more than a decade, starting with neuromuscular diseases. Under his guidance, promising therapies have either entered into various phases of clinical trials or received accelerated approval for use by the Food and Drug Administration (US FDA). He received his PhD in molecular and cellular biology from the University of Melbourne, Australia and post-doctoral training in the laboratories for genetic medicines at Children’s National Medical Center, Washington, DC. He held an Adjunct Professorship in Department of Pharmacology at Dalhousie University, Halifax, Canada, and served as the Principal Director of Research at AGADA Biosciences overseeing their entire pre-clinical trials and clinical testing operations. Currently, he holds a Chief Scientific Officer position at Genepeutic Bio, a CDMO specializing in manufacturing CAR T cells for treatment of various forms of cancer.

Watch now

SPEAKERS

Kitipong Uaesoontrachoon

Chief Scientific Officer at Genepeutic Bio Co.,Ltd

You might also like

Expediting development and manufacture of advanced therapies: critical starting materials case study

Andrew Frazer

21 February

Watch

From concept to clinic: overcoming the challenges of potency assays in cell and gene therapy development

Audrey Chang, Joe Newcome

10 December

in 7

Days

Register

Evaluation and performance of an AAV affinity resin: a CDMO case study

Buzz Lobbezoo, Spyridon Gerontas

12 December 2023

Watch

Positioning early cell therapy programs for clinical success: insights to mitigate risk and ensure GMP readiness

K Watanabe, M Sadik, M Duggan

7 March

Watch

Safeguard your viral vector tech transfer: considerations and case studies

J Cody, F Cuneo, K Taylor

3 October

Watch